What is RNA and how can we use the body's own RNA editing machinery to treat disease? Learn more about the Axiomer® RNA editing technology and how we are creating a new class of medicines.
… diseases. Axiomer enables RNA base editing by recruiting ADAR so your own body can treat disease. Learn more here. … (AONs) have been used as therapeutics for the last few decades. ProQR has built an extensive pipeline of investigational RNA therapies based on the technologies already available. But our scientists have gone beyond that …
… Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing LEIDEN, Netherlands & CAMBRIDGE, … which is related to targeted RNA editing using endogenous ADARs and is part of ProQR’s intellectual property estate …
… against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer™. The opposition … stability and recruit endogenous ADAR to edit the target adenosine. This patent is part of ProQR’s intellectual …
… A. de Boer, Founder and CEO, will participate in the ADAR Editing Panel at the Chardan 7 th Annual Genetic … am – 10:15 am EDT, and a recording of the session will be made available on the Company’s website after the conference. … molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer ® EONs are …
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expects up to four clinical data readouts in 2025 and 2026 across multi
